Frequency pivots after failed trial for hearing loss drug candidate
More than half of the US biotech company’s staff will be dismissed after another failed phase II trial involving its experimental hearing loss treatment.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CHRISTOFFER ØSTERGAARD
US biotech company Frequency Therapeutics has been thrust into an existential crisis following another failed trial involving drug candidate FX-322.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
GN declared winner of major tender in Australia
For subscribers
.jpg)
.jpg&w=384&q=75)
